Cancer |
|
|||
Professor Yehuda G. Assaraf of the Technion Faculty of Biology is the head of the Fred Wyszkowski Cancer Research Laboratory. His primary area of research focuses on deciphering the mechanisms (i.e. genes and proteins) responsible for cancer cells' resistance to anticancer drugs -- the main obstacle to curing cancer. His research could pave the way for designing novel strategies to combat drug-resistant tumors, and lead to tailor-made chemotherapy treatment.
|
|||
The Rappaport Family Institute promotes excellence in biomedical research and technology. In this video, you will learn about many of the incredible projects underway at the institute, including cancer research, molecular genetics, and development of BioRap technologies. Working with the Technion's faculty of medicine, the Rappaport is in a unique position to research and develop life-saving technologies. Their track record of success, allows them to think out of the box and collaborate with global institutions.
|
|||
Professor Chaim Cedar, from the Department Developmental Biology and Cancer Research of the Hebrew University of Jerusalem answers questions. Our genetic information contains an "instruction booklet" of how to make up all the components in our body. But when these instructions are interpreted the wrong way—or gene regulation goes awry—it can cause many diseases, including cancer. In the follow up video to this month's Expert on the Spot, Prof. Chaim Cedar, of the Department of Developmental Biology and Cancer Research at the Faculty of Medicine, answers your questions about the role of gene regulation in cancer.
|
|||
|
|||
Our genetic information contains an "instruction booklet" of how to make up all the components in our body. But when these instructions are interpreted the wrong way—or gene regulation goes awry—it can cause many diseases, including cancer. In this month's Expert on the Spot, Prof. Chaim Cedar, of the Department of Developmental Biology and Cancer Research at the Faculty of Medicine of the Hebrew University in Jerusalem invites you to ask questions about the role of gene regulation in cancer. Dr. Cedar will answer your questions in a follow-up video that will be posted.
|
|||
October marked the launch of the Israel Breast Cancer Collaborative, a major partnership between Susan G. Komen for the Cure, Hadassah International and non-governmental organizations in Israel. The goal is to enhance advocacy, awareness, screening and treatment of breast cancer.
|
|||
Medical researchers in Tel Aviv have identified a substance that can kill cancerous cells without harming healthy ones. So far, experiments have only been carried out on mice, but they hope the discovery may pave the way for more effective cancer treatment. An Israeli research scientist has accidentally discovered a chemical compound that eradicates cancer cells without harming normal cells in the process. The substance may prove to be the long sought-after "holy grail" in the wider field of cancer treatment. For now, it shows promise as a specific weapon against breast cancer. Prof. Malka Cohen-Armon, a biochemist at Tel Aviv University, tells ISRAEL21C that the compound is a component of a family of drugs developed 10 years ago to preserve nerve cells stressed by a stroke or inflammation. But further study showed the drugs were inappropriate for their intended use, and they were released only for research purposes.
|
|||
Dr. Shahar Lev-Ari is a molecular biologist and director of complementary medicine at a leading research hospital in Israel. He discusses his experience with The Work of Byron Katie and a proposed study in cancer research.
|
|||
Cancer therapy is at a whole new level. Prof. Marcelle Machluf, of Technion's Faculty of Biotechnology and Food Engineering, has been using stem cells from bone marrow to produce a drug for treating cancer. These cells are implanted into the body and diffuse the drug into the bloodstream so that the drug finds its way to the tumor. Prof. Machluf discusses the early stages of animal testing and the approach towards a preclinical trial.
|
|||
